1.Patients with known allergies to equine serum or to any component of Equine antiserum <br/ >2.Patients with past medical history of Serum Sickness <br/ >3.Patients with history of anaphylaxis or severe allergic reactions to a vaccine, food, drug, toxin or other exposure <br/ >4.Patients who have received convalescent plasma or immunoglobulin for COVID-19 disease <br/ >5.Patients who have received convalescent plasma or immunoglobulin for conditions other than COVID-19 disease within 3 months prior to first dose of investigational product <br/ >6.Patients who are admitted in the Intensive Care Unit (ICU) or under invasive mechanical ventilation and/or extracorporeal membrane oxygenation at randomization/prior to first dose of investigational product <br/ >7.Patients with severe COVID-19 disease including those with severe pneumonia, moderate to severe Acute Respiratory Distress Syndrome, Sepsis and/or Organ failure <br/ >8.Patients who are expected to be referred to another institution within 72 hours of enrolment, which prevents proper follow-up of that patient <br/ >9.Patients whose progression to death due to COVID-19 disease is imminent and inevitable within the next 24 hours, irrespective of the provision of treatment as assessed by the Investigator <br/ >10.Pregnant or breastfeeding women <br/ >11.Known history of human immunodeficiency virus (Types 1 or 2) antibody, hepatitis B surface antigen, or hepatitis C virus antibody. <br/ >12.Participating in any other study and have received any other investigational medication or device within 30 days prior to randomization or are taking part in a non-medication study which, in the opinion of the Investigator, would interfere with the interpretation of the assessments in this study. <br/ >13.Any other medical condition which in the opinion of the Investigator may affect the patientsâ?? safety or study participation and conduct <br/ >14.Presence of any other severe/uncontrolled concurrent medical condition other than COVID-19 disease which precludes the patient from study participation in the interest of patient safety, as judged by the Investigator. <br/ >15.Receipt of ant COVID-19 vaccine (Licensed/EUL/under trial) <br/ >16.Patients re-infected with SARS-CoV-2/COVID-19 disease. <br/ >

1.Patients with known allergies to equine serum or to any component of Equine antiserum <br/ >2.Patients with past medical history of Serum Sickness <br/ >3.Patients with history of anaphylaxis or severe allergic reactions to a vaccine, food, drug, toxin or other exposure <br/ >4.Patients who have received convalescent plasma or immunoglobulin for COVID-19 disease <br/ >5.Patients who have received convalescent plasma or immunoglobulin for conditions other than COVID-19 disease within 3 months prior to first dose of investigational product <br/ >6.Patients who are admitted in the Intensive Care Unit (ICU) or under invasive mechanical ventilation and/or extracorporeal membrane oxygenation at randomization/prior to first dose of investigational product <br/ >7.Patients with severe COVID-19 disease including those with severe pneumonia, moderate to severe Acute Respiratory Distress Syndrome, Sepsis and/or Organ failure <br/ >8.Patients who are expected to be referred to another institution within 72 hours of enrolment, which prevents proper follow-up of that patient <br/ >9.Patients whose progression to death due to COVID-19 disease is imminent and inevitable within the next 24 hours, irrespective of the provision of treatment as assessed by the Investigator <br/ >10.Pregnant or breastfeeding women <br/ >11.Known history of human immunodeficiency virus (Types 1 or 2) antibody, hepatitis B surface antigen, or hepatitis C virus antibody. <br/ >12.Participating in any other study and have received any other investigational medication or device within 30 days prior to randomization or are taking part in a non-medication study which, in the opinion of the Investigator, would interfere with the interpretation of the assessments in this study. <br/ >13.Any other medical condition which in the opinion of the Investigator may affect the patientsâ?? safety or study participation and conduct <br/ >14.Presence of any other severe/uncontrolled concurrent medical condition other than COVID-19 disease which precludes the patient from study participation in the interest of patient safety, as judged by the Investigator. <br/ >15.Receipt of ant COVID-19 vaccine (Licensed/EUL/under trial) <br/ >16.Patients re-infected with SARS-CoV-2/COVID-19 disease. <br/ >

N/A

N/A

1.Patients with known allergies to equine serum or to any component of Equine antiserum <br/ >2.Patients with past medical history of Serum Sickness <br/ >3.Patients with history of anaphylaxis or severe allergic reactions to a vaccine, food, drug, toxin or other exposure <br/ >4.Patients who have received convalescent plasma or immunoglobulin for COVID-19 disease <br/ >5.Patients who have received convalescent plasma or immunoglobulin for conditions other than COVID-19 disease within 3 months prior to first dose of investigational product <br/ >6.Patients who are admitted in the Intensive Care Unit (ICU) or under invasive mechanical ventilation and/or extracorporeal membrane oxygenation at randomization/prior to first dose of investigational product <br/ >7.Patients with severe COVID-19 disease including those with severe pneumonia, moderate to severe Acute Respiratory Distress Syndrome, Sepsis and/or Organ failure <br/ >8.Patients who are expected to be referred to another institution within 72 hours of enrolment, which prevents proper follow-up of that patient <br/ >9.Patients whose progression to death due to COVID-19 disease is imminent and inevitable within the next 24 hours, irrespective of the provision of treatment as assessed by the Investigator <br/ >10.Pregnant or breastfeeding women <br/ >11.Known history of human immunodeficiency virus (Types 1 or 2) antibody, hepatitis B surface antigen, or hepatitis C virus antibody. <br/ >12.Participating in any other study and have received any other investigational medication or device within 30 days prior to randomization or are taking part in a non-medication study which, in the opinion of the Investigator, would interfere with the interpretation of the assessments in this study. <br/ >13.Any other medical condition which in the opinion of the Investigator may affect the patientsâ?? safety or study participation and conduct <br/ >14.Presence of any other severe/uncontrolled concurrent medical condition other than COVID-19 disease which precludes the patient from study participation in the interest of patient safety, as judged by the Investigator. <br/ >15.Receipt of ant COVID-19 vaccine (Licensed/EUL/under trial) <br/ >16.Patients re-infected with SARS-CoV-2/COVID-19 disease. <br/ >

1.Patients with known allergies to equine serum or to any component of Equine antiserum <br/ >2.Patients with past medical history of Serum Sickness <br/ >3.Patients with history of anaphylaxis or severe allergic reactions to a vaccine, food, drug, toxin or other exposure <br/ >4.Patients who have received convalescent plasma or immunoglobulin for COVID-19 disease <br/ >5.Patients who have received convalescent plasma or immunoglobulin for conditions other than COVID-19 disease within 3 months prior to first dose of investigational product <br/ >6.Patients who are admitted in the Intensive Care Unit (ICU) or under invasive mechanical ventilation and/or extracorporeal membrane oxygenation at randomization/prior to first dose of investigational product <br/ >7.Patients with severe COVID-19 disease including those with severe pneumonia, moderate to severe Acute Respiratory Distress Syndrome, Sepsis and/or Organ failure <br/ >8.Patients who are expected to be referred to another institution within 72 hours of enrolment, which prevents proper follow-up of that patient <br/ >9.Patients whose progression to death due to COVID-19 disease is imminent and inevitable within the next 24 hours, irrespective of the provision of treatment as assessed by the Investigator <br/ >10.Pregnant or breastfeeding women <br/ >11.Known history of human immunodeficiency virus (Types 1 or 2) antibody, hepatitis B surface antigen, or hepatitis C virus antibody. <br/ >12.Participating in any other study and have received any other investigational medication or device within 30 days prior to randomization or are taking part in a non-medication study which, in the opinion of the Investigator, would interfere with the interpretation of the assessments in this study. <br/ >13.Any other medical condition which in the opinion of the Investigator may affect the patientsâ?? safety or study participation and conduct <br/ >14.Presence of any other severe/uncontrolled concurrent medical condition other than COVID-19 disease which precludes the patient from study participation in the interest of patient safety, as judged by the Investigator. <br/ >15.Receipt of ant COVID-19 vaccine (Licensed/EUL/under trial) <br/ >16.Patients re-infected with SARS-CoV-2/COVID-19 disease. <br/ >